Primecap Management Co. CA Has $199.70 Million Holdings in Stryker Corporation $SYK

Primecap Management Co. CA lifted its position in shares of Stryker Corporation (NYSE:SYK) by 16.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 504,762 shares of the medical technology company’s stock after purchasing an additional 69,912 shares during the quarter. Primecap Management Co. CA owned 0.13% of Stryker worth $199,699,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of Stryker by 1.3% during the second quarter. Vanguard Group Inc. now owns 33,500,571 shares of the medical technology company’s stock valued at $13,253,831,000 after buying an additional 440,607 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Stryker by 1.1% in the second quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock valued at $2,910,445,000 after purchasing an additional 79,654 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Stryker by 13.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Stryker by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after buying an additional 83,954 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider directly owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 522,453 shares of company stock worth $185,516,867. 5.90% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of SYK opened at $359.53 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm has a market cap of $137.49 billion, a PE ratio of 47.62, a PEG ratio of 2.66 and a beta of 0.94. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock’s fifty day moving average price is $370.62 and its two-hundred day moving average price is $381.03.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. On average, equities research analysts forecast that Stryker Corporation will post 13.47 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SYK. Redburn Partners set a $420.00 price objective on shares of Stryker in a report on Thursday, September 18th. Royal Bank Of Canada reissued an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Rothschild Redb upgraded Stryker to a “hold” rating in a research note on Thursday, September 18th. Finally, UBS Group set a $408.00 target price on Stryker in a research note on Monday, October 13th. Thirteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.